<DOC>
	<DOCNO>NCT00681928</DOCNO>
	<brief_summary>RATIONALE : Gathering information cognitive function time postmenopausal woman breast cancer may help doctor learn long-term effect aromatase inhibitor therapy plan best treatment . PURPOSE : This clinical trial study cognitive function old postmenopausal woman stage I , stage II , stage III breast cancer receive hormone therapy healthy volunteer .</brief_summary>
	<brief_title>Cognitive Function Older Women With Stage I , Stage II , Stage III Breast Cancer Receiving Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Explore impact treatment aromatase inhibitor cognitive function postmenopausal woman stage I-III breast cancer v cancer-free , age-matched healthy volunteer . OUTLINE : Patients receive adjuvant anastrozole letrozole absence disease progression unacceptable toxicity . Patients healthy volunteer undergo cognitive function test consist neuropsychological battery test complete self-reported questionnaire ( e.g. , Squire Memory Self-Rating Questionnaire , FACT-B Quality Life Measure ) regard cognitive ability , quality life , fatigue , psychosocial status . Patients healthy volunteer also undergo geriatric assessment baseline 6 month initiation aromatase inhibitor therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Patient diagnose breast cancer Stage IIII disease Estrogen receptor and/or progesterone receptorpositive Planning start treatment anastrozole letrozole Agematched healthy volunteer ( control ) No history breast cancer Not receive adjuvant aromatase inhibitor therapy PATIENT CHARACTERISTICS : Postmenopausal Able converse , write , read English No claustrophobia ( patient participate PET scan correlative study ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior hormonal therapy , include estrogen replacement therapy No previous treatment CNS radiation</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>